Active Ingredient(s): Ibrexafungerp Citrate
FDA Approved: * June 1, 2021
Pharm Company: * SCYNEXIS
Category: Antifungal

Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection).[1] It is taken by mouth.[1] Ibrexafungerp is a triterpenoid antifungal.[1] Ibrexafungerp was approved for medical use in the United States in June 2021.[1][2] It is the first approved drug in a novel antifungal class.[2] Contents 1 Medical uses 2... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Brexafemme 150 mg Oral Tablet, Film Coated
NDC: 75788-115
Scynexis, Inc.